Recce Pharmaceuticals Ltd

Recce Pharmaceuticals (ASX: RCE) has commenced patient dosing for a registrational Phase 3 clinical trial of its RECCE 327 topical gel (R327G) to treat diabetic foot infections (DFI). The company has activated five clinical study sites across one of the world’s largest DFI patient populations in Indonesia, where estimates place the prevalence of diabetes at 20.9 […]

All roads will lead to Singapore in early October with the important Spark Plus Aussie Equities Day investment show being staged in the lead-up to the local grand prix motoring event. The 2025 Spark Plus Aussie Equities Day is the 4th installment of their flagship event which aims to introduce a range of Australian companies to […]

Recce Pharmaceuticals (ASX: RCE) has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel (R327G) for the treatment of acute bacterial skin and skin structure infections. The company designed the open-label trial to assess the efficacy and safety of R327G in 30 male and female patients, with […]

One week since announcing two of its compounds will be used in an upcoming antiviral SARS-CoV-2 screening program, Recce Pharmaceuticals (ASX: RCE) has penned an agreement with US-based precision medicine company Path BioAnalytics for the study of its RECCE 327 and RECCE 529 antibiotics against SARS-CoV-2, the strain of coronavirus that causes COVID-19. The development […]